Vascular Biogenics Profit Margin

The latest profit margin for VBLT is -7734.51% as of June 2024. That compares with -4432.55% in the prior-year period — down 74.5% year over year. That is below the Healthcare sector average of 10.58%. Investors often review this figure alongside Vascular Biogenics's historical trend and sector peers before judging valuation or financial health.

Over the past year, VBLT's profit margin moved from -4432.55% to -7734.51% — a 74.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Vascular Biogenics's valuation or profitability profile.

Against Healthcare companies, VBLT currently prints -7734.51% for profit margin, while the sector average sits near 10.58%. That is roughly 73201.8% below the sector mean. Large gaps often invite a closer look at Vascular Biogenics's growth, margins, and balance sheet.

Profit Margin shows how effectively Vascular Biogenics converts resources into returns. At -7734.51%, VBLT may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -4432.55% in the prior-year period — down 74.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting VBLT's profit margin (-7734.51%), review year-over-year change from -4432.55%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.